Skip to main content

Table 3 Evaluation of bortezomib in combination with other therapies.

From: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Type of therapy Drug or agent Cancer References
Chemotherapy 5-Fluorouracil, cisplatin, paclitaxel, doxorubicin, cyclophosphamide Breast, lung Teicher et al [45], 1999
  Melphalan, doxorubicin, dexamethasone Multiple myeloma Hideshima et al [15], 2001
Mitsiades et al [50], 2003
Ma et al [20], 2003
  Topoisomerase inhibitor: irinotecan Colon Pancreatic Cusack et al [30], 2001
Shah et al [24], 2001
  Gemcitabine Pancreatic Bladder Bold et al [48], 2001
Kamat et al [51], 2004
  Pegylated liposomal doxorubicin Breast Small et al [52], 2004
  Docetaxel Pancreatic Nawrocki et al [53], 2004
  Temozolomide Melanoma Amiri et al [49], 2004
Radiation therapy   Breast Colon Prostate Teicher et al [45], 1999
Russo et al [16], 2001
Pervan et al [54], 2001
Immunotherapy Daclizumab Adult T-cell leukemia Tan and Waldmann [19], 2002
Novel agents TRAIL/Apo2L Multiple myeloma, myeloid leukemia, renal Mitsiades et al [55], 2001
Sayers et al [56], 2003
  HSP90 inhibitor: 17-AAG Breast Mimnaugh et al [39], 2004
  HDAC inhibitors: SAHA, sodium butyrate CML, multiple myeloma, lung Denlinger et al [40], 2004
Yu et al [57], 2003
Mitsiades et al [58], 2004
Denlinger et al [59], 2004
Pei et al [60], 2004
Transplantation Allogeneic BMT Leukemia Sun et al [61], 2004
  1. HSP = heat shock protein; HDAC = histone deacetylase; CML = chronic myelogenous leukemia; BMT = bone marrow transplantation.